Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA DEMONSTRATE POTENT IN VIVO GENE EDITING OF HEMATOPOIETIC STEM CELLS (HSCS) IN THE BONE MARROW WITH SYSTEMIC DELIVERY IN PRECLINICAL MURINE MODELS USING FUSOGEN TECHNOLOGY

SANA BIOTECHNOLOGY ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF IN VIVO GENE EDITING OF HUMAN HEMATOPOIETIC STEM CELLS IN PRECLINICAL MODELS USING THE FUSOGEN PLATFORM

SEATTLE, NOV. 24, 2025 (GLOBE NEWSWIRE) -- SANA BIOTECHNOLOGY, INC. (NASDAQ: SANA), A COMPANY FOCUSED ON CHANGING THE POSSIBLE FOR PATIENTS THROUGH ENGINEERED CELLS, TODAY ANNOUNCED THAT IT WILL WEBCAST ITS PRESENTATIONS AT TWO INVESTOR CONFERENCES IN DECEMBER. THE PRESENTATIONS WILL FEATURE A BUSINESS OVERVIEW AND UPDATE BY STEVE HARR, SANA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.

SANA BIOTECHNOLOGY TO PRESENT AT DECEMBER 2025 INVESTOR CONFERENCES

RESEARCH TRIANGLE PARK, N.C. AND CAMBRIDGE, MASS.

IQVIA AND FLAGSHIP PIONEERING ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH LIFE SCIENCES COMPANIES

SEATTLE, AUG. 26, 2025 (GLOBE NEWSWIRE) -- SANA BIOTECHNOLOGY, INC. (NASDAQ: SANA), A COMPANY FOCUSED ON CHANGING THE POSSIBLE FOR PATIENTS THROUGH ENGINEERED CELLS, TODAY ANNOUNCEDTHAT IT WILL WEBCAST ITS PRESENTATIONS AT FOUR INVESTOR CONFERENCES IN SEPTEMBER. THE PRESENTATIONS WILL FEATURE A BUSINESS OVERVIEW AND UPDATE.

SANA BIOTECHNOLOGY TO PRESENT AT SEPTEMBER 2025 INVESTOR CONFERENCES

SEATTLE, AUG. 20, 2025 (GLOBE NEWSWIRE) -- SANA BIOTECHNOLOGY, INC. (NASDAQ: SANA) (SANA), A COMPANY FOCUSED ON CHANGING THE POSSIBLE FOR PATIENTS THROUGH ENGINEERED CELLS, TODAY ANNOUNCED THAT IT HAS CLOSED THE SALE OF 3,358,208 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.35 PER SHARE, PURSUANT TO THE EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN CONNECTION WITH SANA'S PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING, WHICH CLOSED ON AUGUST 8, 2025. ALL OF THE SHARES WERE SOLD BY SANA. TOTAL GROSS PROCEEDS FROM THE OFFERING, INCLUDING THE FULL EXERCISE OF THE UNDERWRITERS' OPTION, WERE APPROXIMATELY $86.3 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES.

SANA BIOTECHNOLOGY ANNOUNCES CLOSING OF FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SEATTLE, AUG. 06, 2025 (GLOBE NEWSWIRE) -- SANA BIOTECHNOLOGY, INC. (NASDAQ: SANA) (SANA), A COMPANY FOCUSED ON CHANGING THE POSSIBLE FOR PATIENTS THROUGH ENGINEERED CELLS, TODAY ANNOUNCED THAT IT HAS PRICED ITS UNDERWRITTEN PUBLIC OFFERING OF 20,895,522 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.35 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 1,492,537 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.3499 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT. ALL OF THE SHARES AND PRE-FUNDED WARRANTS ARE TO BE SOLD BY SANA. IN ADDITION, SANA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 3,358,208 SHARES OF ITS COMMON STOCK. THE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $75.0 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES AND EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT AUGUST 8, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

SANA BIOTECHNOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING

SEATTLE, AUG. 06, 2025 (GLOBE NEWSWIRE) -- SANA BIOTECHNOLOGY, INC. (NASDAQ: SANA) (SANA), A COMPANY FOCUSED ON CHANGING THE POSSIBLE FOR PATIENTS THROUGH ENGINEERED CELLS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, SANA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $11.25 MILLION OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE PROPOSED OFFERING WILL BE SOLD BY SANA. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

SANA BIOTECHNOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

FOLLOWING FDA INPUT, SERES SUBMITTED PHASE 2 STUDY PROTOCOL TO FDA FOR SER-155 FOR THE PREVENTION OF BLOODSTREAM INFECTIONS (BSIS) IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) TO TREAT HEMATOLOGICAL MALIGNANCIES SERES ENGAGING WITH MULTIPLE PARTIES REGARDING VARIOUS DEAL STRUCTURES, INCLUDING POTENTIAL BUSINESS DEVELOPMENT AND PARTNERSHIPS, INTENDED TO SECURE CAPITAL AND OTHER RESOURCES TO ENABLE THE CLINICAL ADVANCEMENT OF SER-155 AND ADDITIONAL LIVE BIOTHERAPEUTIC PRODUCT CANDIDATES SERES RECEIVED THE $25 MILLION INSTALLMENT PAYMENT, AS EXPECTED, FROM NESTL HEALTH SCIENCE IN JULY 2025 CONFERENCE CALL AT8:30 A.M. ETTODAY CAMBRIDGE, MASS.

SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

DATA DEMONSTRATE THAT SANA'S HYPOIMMUNE (HIP)-MODIFIED PANCREATIC ISLET CELLS, TRANSPLANTED WITH NO IMMUNOSUPPRESSION, PERSIST AND FUNCTION OVER TIME IN PATIENT WITH TYPE 1 DIABETES

SANA BIOTECHNOLOGY ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE OF GROUNDBREAKING CLINICAL DATA FROM TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION OF HYPOIMMUNE-MODIFIED, INSULIN-PRODUCING ISLET CELLS IN PATIENT WITH TYPE 1 DIABETES

GROUNDBREAKING FIRST-IN-HUMAN STUDY ESTABLISHES POTENTIAL TO TREAT TYPE 1 DIABETES BY TRANSPLANTING INSULIN-SECRETING CELLS WITHOUT IMMUNOSUPPRESSION

Sana Biotechnology, Inc.

SANA

Price

Financial Reports

No items found.

Press Releases

Sana Biotechnology, Inc.

SANA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SANA